97 Ampullary cancer, though rare, has prompted debates over the effectiveness of adjuvant treatments following surgical resection. A new systematic review and meta-analysis, analysing 21 studies involving 3,971 patients, sheds light on the nuanced benefits of these therapies. The findings highlight the potential survival benefits for a specific group of patients while reaffirming the need for further research. The findings were published in the journal Hepatobiliary & Pancreatic Diseases International. Ampullary cancer accounts for a small percentage of gastrointestinal cancers. It is generally treated with surgical resection, typically pancreaticoduodenectomy. While surgery often provides favourable outcomes, recurrence remains a significant concern. This has led to the exploration of adjuvant therapies, including chemotherapy and chemoradiotherapy, aimed at improving survival rates and reducing recurrence. However, past research has produced conflicting results regarding their efficacy. The recent meta-analysis provides clarity by focusing on overall survival (OS) and recurrence-free survival (RFS). The study concluded that adjuvant treatments do not significantly impact survival or recurrence when applied broadly across all cases. However, the benefits became evident in a subgroup of patients with lymph nodal involvement. For these patients, the hazard ratio for overall survival improved, suggesting that adjuvant treatments are particularly advantageous for this high-risk group. Interestingly, the study also delved into the impact of different adjuvant treatment strategies. Neither chemotherapy alone nor the combination of chemotherapy and radiotherapy significantly improved outcomes across the general patient population. This reinforces the notion that a tailored approach is essential, especially for nodal-positive cases. The findings align with current guidelines recommending adjuvant therapies for advanced-stage ampullary cancer. Patients with lymph node involvement, categorised as stage III or higher, benefit the most from such treatments. The study also underscores the prognostic importance of lymph node status. Research suggests that the ratio of affected lymph nodes to those removed during surgery could serve as a critical factor in determining the necessity of adjuvant therapy. Despite these advancements, the meta-analysis acknowledges several limitations. Most studies included were retrospective, introducing potential biases. Additionally, the low incidence of ampullary cancer complicates the execution of large-scale randomised controlled trials, which are considered the gold standard in clinical research. Nevertheless, the aggregated data provide valuable insights, reinforcing the importance of adjuvant therapy for selected patients. The study calls for further research to refine the criteria for adjuvant therapy. Future investigations should consider factors such as lymph node ratio and histological subtypes of ampullary cancer. The goal is to develop personalised treatment protocols that maximise survival while minimising unnecessary interventions. Ampullary cancer remains a challenging condition to treat, but this analysis marks a significant step towards improving outcomes for those with nodal involvement. By tailoring adjuvant therapies to high-risk patients, clinicians can enhance survival rates and offer a better prognosis.